(Q36532437)

14 August 2017

1 reference

title

Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. (English)

1 reference

14 August 2017

1 reference

Chun-Jen Liu

1

0 references

Chen Pei-jer

object named as

Pei-Jer Chen

series ordinal

3

0 references

Ding-Shinn Chen

object named as

Ding-Shinn Chen

series ordinal

2

0 references

publication date

1 May 2006

1 reference

Journal of Clinical Virology

14 August 2017

published in

1 reference

14 August 2017

volume

36 Suppl 1

1 reference

14 August 2017

page(s)

S33-44

1 reference

Occult hepatitis B virus infection: implications in transfusion

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Significance of isolated hepatitis B core antibody in blood donors from São Paulo

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Hepatitis B epidemiology in Asia, the Middle East and Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Hepatitis B core antigen antibody as an indicator of a low grade carrier state for hepatitis B virus in a Saudi Arabian blood donor population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Seroepidemiology of HBV and HCV infection in Jakarta, Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Current and emerging infectious risks of blood transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti‐HBc titer and PCR‐amplified HBV DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Epidemiology of hepatitis B virus infection in the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

From hepatitis to hepatoma: lessons from type B viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Occult hepatitis B virus infection: a hidden menace?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Hepatitis B virus with X gene mutation is associated with the majority of serologically "silent" non-b, non-c chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Evaluating the cost-effectiveness of clinical and public health measures

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Serological pattern ?anti-HBc alone?: Report on a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Occult hepatitis B virus infection and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Prevalence of markers of hepatitis B in the adult German population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Identification of different states of hepatitis B virus infection with a quantitative PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

The risks of transfusion-transmitted infection: direct estimation and mathematical modelling

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

HBV: amplified and back in the blood safety spotlight

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allograft

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Chronic hepatitis B virus infection in Asian countries

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Occult hepatitis B virus infection in a North American community-based population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High prevalence of HBV infectivity in blood donors detected by the dot blot hybridisation assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989-1996

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Estimates of chronic hepatitis B virus infection in Australia, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Nucleic acid amplification testing of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Serum hepatitis B virus DNA in hepatitis B virus seropositive and seronegative patients with normal liver function

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

[Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)]

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

NAT for HBV and anti-HBc testing increase blood safety

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Response to hepatitis B vaccine in HBsAg/anti-HBs negative and anti-HBc positive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Serological markers of hepatitis B, C, and E viruses and human immunodeficiency virus type-1 infections in pregnant women in Bali, Indonesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High prevalence of hepatitis B virus (HBV) among male blood donors in a developing country: urgent need for systematic screening

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Post-transfusional anti-HCV-negative non-A non-B hepatitis (II) serological and polymerase chain reaction analysis for hepatitis C and hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

1 reference

7 January 2021

Detection of hepatitis B virus DNA in blood units with anti-HBc as the only positive serological marker

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Blood transfusion in developing countries: problems, priorities and practicalities

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Hepatitis B virus markers in anti-HBc only positive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Persistent viremia after recovery from self-limited acute hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980007-7

7 January 2021

10.1016/S1386-6532(06)80007-7

Identifiers

DOI

1 reference

14 August 2017

1 reference